According to Greek media reports, Papastratos, the largest cigarette manufacturer and distributor in Greece and a subsidiary of Philip Morris International, achieved a net sales revenue of 657 million euros in 2022, a nearly 40% increase from 469 million euros in 2021. Despite a 58% increase in sales costs, rising from 270 million euros to 426 million euros, the company's gross profit also grew from 200 million euros to 231 million euros.
In summary, the company's sales in 2022 reached 1.58 billion euros, marking an increase from 1.364 billion euros in 2021. Domestic sales accounted for the majority of total sales at 1.251 billion euros, followed by exports at 329 million euros, a significant increase compared to 181 million euros in 2021.
Since 2017, Papastratos' investment plan at its Aspropyrgos factory has significantly increased the production volume of IQOS products.
In 2021, the company began a €125 million investment to improve their production line and manufacture the next generation IQOS products. With an additional investment of €160 million secured in 2022, a total of six refurbished production lines and two brand new lines were operational by the end of 2022.
In February 2023, the company announced an additional investment of 200 million euros in its Aspropyrgos plant, adding four production lines and creating 300 new jobs in the local area. This investment is also expected to generate an additional 300 million euros in exports.
Of note, Papastratos has recently been rebranded as the operating headquarters for PMI in Southeastern Europe, encompassing 12 countries including Greece, Bulgaria, Romania, Cyprus, Slovakia, Serbia, Bosnia and Herzegovina, North Macedonia, Albania, and Montenegro.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
